ALK is a global research-driven pharmaceutical company focusing on allergy prevention, diagnosis and treatment. Our mission is to improve the quality of life of people suffering from allergy by developing pharmaceutical products targeted at the cause of allergy. ALK is the world leader in allergy immunotherapy (allergy vaccination) - a unique treatment of the underlying cause of allergy. The treatment induces a protective immune response that provides sustained symptom relief and reduces the risk of developing asthma. ALK provides allergy immunotherapy administered as injections, sublingual drops and tablets, the most recent, best documented and most convenient treatment for patients. The product portfolio also includes an adrenaline pen for the treatment of severe allergic reactions (anaphylaxis). Every year, ALK invests approx. 20% of revenue in research and development aimed at developing new, evidence based allergy immunotherapy products. Our R&D pipeline includes tablet based allergy immunotherapy products against ragweed, house dust mite and tree pollen allergy. ALK has entered into partnership agreements with Merck and Torii Pharmaceutical Co., Ltd. to develop, register and commercialise tablets in North America and Japan. ALK has approx. 1,850 employees with subsidiaries, production facilities and distributors worldwide. The company headquarters is in Denmark and is listed on NASDAQ OMX Copenhagen (OMX: ALK B).
Market capitalization (24-Jul-2017)
Closing share price (24-Jul-2017)